For patients at high risk of OHSS after triggering of final oocyte maturation, particularly with hCG, oral cabergoline can reduce the risk of developing OHSS, whilst there is also low-level evidence to support the use of GnRH antagonists after oocyte collection. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.